{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:13:54Z","timestamp":1787141634282,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RC-2022-2773372"],"award-info":[{"award-number":["RC-2022-2773372"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.prp.2023.155008","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T07:43:10Z","timestamp":1702021390000},"page":"155008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab."],"prefix":"10.1016","volume":"253","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5169-3631","authenticated-orcid":false,"given":"Veronica","family":"Mollica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Tassinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Valeria","family":"Marchese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Giunchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais","family":"Maloberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Rosellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario De","family":"Biase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2023.155008_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.prp.2023.155008_bib2","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2147\/CMAR.S287904","article-title":"Treatment options for metastatic urothelial carcinoma after first-line chemotherapy","volume":"14","author":"Tassinari","year":"2022","journal-title":"Cancer Manag. Res."},{"issue":"19","key":"10.1016\/j.prp.2023.155008_bib3","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2023.155008_bib4","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.prp.2023.155008_bib5","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.prp.2023.155008_bib6","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1038\/s41591-021-01579-0","article-title":"Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN bladder 100 trial","volume":"27","author":"Powles","year":"2021","journal-title":"Nat. Med"},{"issue":"10","key":"10.1016\/j.prp.2023.155008_bib7","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1158\/1078-0432.CCR-21-3089","article-title":"Putative biomarkers of clinical benefit with pembrolizumab in advanced urothelial cancer: results from the KEYNOTE-045 and KEYNOTE-052 landmark trials","volume":"28","author":"Bellmunt J","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"7867","key":"10.1016\/j.prp.2023.155008_bib8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.prp.2023.155008_bib9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/cancers13010131","article-title":"Immune checkpoint inhibitors for the treatment of bladder cancer","volume":"13","author":"Lopez-Beltran","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.prp.2023.155008_bib10","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.3390\/curroncol29050283","article-title":"Genomics and immunomics in the treatment of urothelial carcinoma","volume":"29","author":"Mollica","year":"2022","journal-title":"Curr. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2023.155008_bib11","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.euf.2020.08.001","article-title":"Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma","volume":"7","author":"Necchi","year":"2021","journal-title":"Eur. Urol. Focus"},{"issue":"7","key":"10.1016\/j.prp.2023.155008_bib12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41580-020-0234-z","article-title":"Regulation of human telomerase in homeostasis and disease","volume":"21","author":"Roake","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.prp.2023.155008_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","article-title":"Hallmarks of aging: an expanding universe","volume":"186","author":"L\u00f3pez-Ot\u00edn","year":"2023","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.prp.2023.155008_bib14","doi-asserted-by":"crossref","first-page":"19542","DOI":"10.18632\/oncotarget.4295","article-title":"The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.prp.2023.155008_bib15","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1038\/emboj.2012.132","article-title":"Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions","volume":"31","author":"Suram","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.prp.2023.155008_bib16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.humpath.2022.06.005","article-title":"Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management","volume":"133","author":"Cheng","year":"2023","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2023.155008_bib17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ebiom.2019.05.004","article-title":"Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer","volume":"44","author":"Avogbe","year":"2019","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.prp.2023.155008_bib18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/bjc.2017.210","article-title":"Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine","volume":"117","author":"Descotes","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"41","key":"10.1016\/j.prp.2023.155008_bib19","doi-asserted-by":"crossref","first-page":"67435","DOI":"10.18632\/oncotarget.11883","article-title":"Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up","volume":"7","author":"Critelli","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.prp.2023.155008_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002127","article-title":"TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor","volume":"9","author":"de Kouchkovsky","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2023.155008_bib21","article-title":"A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy","volume":"236","author":"Marchese","year":"2022","journal-title":"Pathol. Res Pr."},{"issue":"2","key":"10.1016\/j.prp.2023.155008_bib22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2013.10.038","article-title":"Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study","volume":"65","author":"Wu","year":"2014","journal-title":"Eur. Urol."},{"issue":"11","key":"10.1016\/j.prp.2023.155008_bib23","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/14737159.2022.2154148","article-title":"Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers","volume":"22","author":"Marchese","year":"2022","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"8","key":"10.1016\/j.prp.2023.155008_bib24","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.ejca.2015.03.010","article-title":"Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation","volume":"51","author":"Huang","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"15","key":"10.1016\/j.prp.2023.155008_bib25","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1073\/pnas.1303607110","article-title":"TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal","volume":"110","author":"Killela","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.prp.2023.155008_bib26","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00401-017-1690-1","article-title":"Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT","volume":"133","author":"Pekmezci","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.prp.2023.155008_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ijc.30042","article-title":"TERT promoter mutations in melanoma survival","volume":"139","author":"Nagore","year":"2016","journal-title":"Int. J. Cancer"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823007094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823007094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T11:52:32Z","timestamp":1730893952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033823007094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":27,"alternative-id":["S0344033823007094"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2023.155008","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2023.155008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155008"}}